Skip to content
OpenCapital
Get started

Achieve Life Sciences ACHV Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value at other companies

CHE
ChemedCHE
85.8-25.1%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$1.38-55.5%
HTF
Heartflow, Inc. Common StockHTFL
15.9+124%
Belden logo
BeldenBDC
$39.44+80.5%
KEE
Keel Infrastructure Corp. Common StockKEEL
$0.72-35.7%
Frequency Electronics logo
Frequency ElectronicsFEIM
$0.00—

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Cash & equivalents$28.1M+116%
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0—
Free cash flow-$12.4M—

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Debt / equity0.5×+0.4×
Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Achieve Life Sciences’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value?
Achieve Life Sciences (ACHV) reported share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value of $3.81 in Q4 2025.
How has Achieve Life Sciences's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value changed year-over-year?
Achieve Life Sciences's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value increased by 13.7% year-over-year, from $3.35 to $3.81.
What does share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value mean?
The weighted-average fair value per share of stock options granted during the period, calculated at the date of grant. This metric provides a standardized measure of the economic value provided to employees through option-based compensation.